EMA begins safety review of bluebird gene therapy following AML case in related therapy

The EMA officially announced early Friday that it will look into the safety of bluebird bio’s gene therapy Zynteglo, which is authorized in the EU to treat a rare blood condition, after an investigational gene therapy the company is developing for sickle cell led to a case of acute myeloid leukemia. Both Zynteglo and the gene therapy in development use the same viral vector.